Navigation Links
New Study Results Presented on Dexlansoprazole and Lansoprazole Effects on Plavix® (clopidogrel bisulfate)
Date:4/5/2011

NEW ORLEANS, April 5, 2011 /PRNewswire/ -- Takeda Pharmaceuticals North America, Inc. (Takeda) announced the presentation of new study results, which evaluated the potential inhibitory effects of certain proton pump inhibitors (PPIs) on Plavix (clopidogrel bisulfate). The results showed that in healthy subjects, clopidogrel's active metabolite and inhibition of platelet function were reduced less by the co-administration of clopidogrel with dexlansoprazole or lansoprazole, rather than esomeprazole. The randomized, open-label, two-period, crossover study was designed to assess the effects of selected PPIs, a class of drugs used to treat gastroesophageal reflux disease, on the pharmacokinetics (PK) and pharmacodynamics (PD) of clopidogrel. Clopidogrel is a platelet-inhibiting drug that is indicated for the reduction of atherothrombotic events in patients with acute coronary syndromes, recent myocardial infarction, recent stroke or established peripheral arterial disease. The results were presented at the American College of Cardiology (ACC) 2011 60th Annual Scientific Session in New Orleans.

Studies have shown that PPIs may inhibit a liver enzyme (CYP2C19) important for the metabolism of clopidogrel. With CYP2C19 inhibition, clopidogrel may have reduced antiplatelet effects, potentially reducing its effectiveness. Because PPIs differ in their degree of inhibition of CYP2C19, using omeprazole as a positive control, this study evaluated the effect of several PPIs (dexlansoprazole, lansoprazole and esomeprazole) on the steady-state PK and PD of clopidogrel in healthy subjects.

"We conducted this study to look at the effect of select PPIs on Plavix and add to the growing body of evidence on the potential interaction between these drugs," said lead investigator Alan D. Michelson, M.D., Professor of Pediatrics at Harvard Medical School and Director of the Center for Platelet Research Studies at Children's Hospital Boston. "We found that in healthy subjects
'/>"/>

SOURCE Takeda Pharmaceuticals North America, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. BioDelivery Sciences Announces Completion of Recruitment in BEMA Buprenorphine Phase 3 Chronic Pain Study
2. Parent Project Muscular Dystrophy Awards $750,000 Grant to Sildenafil/Taladafil Study
3. Major New Study Shows Aortic Valve Replacement Via Catheter Produces Better Outcomes Than Traditional Open-Heart Surgery
4. Laser Spine Institute Directors And Surgeon Publish Case Study
5. ViroPharma Initiates Phase 2 Study of C1 Esterase Inhibitor [Human] for Treatment of Antibody-Mediated Rejection (AMR)
6. Initiation of FLINT Announced by NIDDK: Study of Intercept Pharmaceuticals Obeticholic Acid (INT-747) in NASH
7. Detroit Medical Center Becomes First in Southeast Michigan to Study an Implantable Device, Designed to Reduce Patient Time to the ER and Improve Survival Rates From Heart Attack in High-Risk Patients
8. Mersana Therapeutics Initiates Phase 1b Extension Study of XMT-1001 in Gastric Cancer and Non-Small Cell Lung Cancer
9. $2 Million Awarded to Duke University Prevention Epicenter to Study Reduction of Healthcare-Associated Infections Using Tru-D, Total Room Ultraviolet Disinfection
10. Managed Health Care Associates, Inc. (MHA) Released Results of Fourth Annual Independent Long Term Care Member Study with Highlights of Specialty Pharmaceutical Product Utilization
11. GeNO LLC Initiates Study of Inhaled NITROSYL™ Nitric Oxide in Idiopathic Pulmonary Fibrosis (PH-IPF) and Pulmonary Arterial Hypertension (PAH) Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)... SCHOFIELD, Wis. , July 30, 2014 /PRNewswire/ ... researcher, developer, and marketer of over-the-counter (OTC) medicinal ... is rebranding the LipiGesic ® M name along with ... will be replaced with the trademarked name MigraPure ... and color palette of PuraMed,s homeopathic, natural migraine ...
(Date:7/30/2014)... 30, 2014  El Camino Hospital, a leader in ... utilizing the Leaf Patient Monitoring system to help prevent ... of patients susceptible to bed sores. The ... study of the system, which showed dramatic improvement in ... regularly is the one of the most effect ways ...
(Date:7/30/2014)... -- InnoPharma, Inc. today announced the first generic launch of ... injection), in Canada.  Olanzapine is indicated for the rapid ... schizophrenia or bipolar I mania. As the ... into an agreement with Sandoz Canada Inc., pursuant to ... market and distribute Olanzapine Injection in Canada ...
Breaking Medicine Technology:PuraMed BioScience Rebrands its Natural Migraine Relief Medication, LipiGesic M 2PuraMed BioScience Rebrands its Natural Migraine Relief Medication, LipiGesic M 3El Camino Hospital Utilizes Cutting-Edge Leaf Patient Monitor System to Help Reduce Risk of Pressure Ulcers 2El Camino Hospital Utilizes Cutting-Edge Leaf Patient Monitor System to Help Reduce Risk of Pressure Ulcers 3InnoPharma Announces Launch of Olanzapine for Injection, 10mg/vial in Canada 2
... ... ... ... ...
... ... ... ... ...
Cached Medicine Technology:Par Pharmaceutical Companies Reports Adjusted EPS of $0.65 for Fourth Quarter 2009 2Par Pharmaceutical Companies Reports Adjusted EPS of $0.65 for Fourth Quarter 2009 3Par Pharmaceutical Companies Reports Adjusted EPS of $0.65 for Fourth Quarter 2009 4Par Pharmaceutical Companies Reports Adjusted EPS of $0.65 for Fourth Quarter 2009 5Par Pharmaceutical Companies Reports Adjusted EPS of $0.65 for Fourth Quarter 2009 6Par Pharmaceutical Companies Reports Adjusted EPS of $0.65 for Fourth Quarter 2009 7Par Pharmaceutical Companies Reports Adjusted EPS of $0.65 for Fourth Quarter 2009 8Par Pharmaceutical Companies Reports Adjusted EPS of $0.65 for Fourth Quarter 2009 9Par Pharmaceutical Companies Reports Adjusted EPS of $0.65 for Fourth Quarter 2009 10Par Pharmaceutical Companies Reports Adjusted EPS of $0.65 for Fourth Quarter 2009 11Par Pharmaceutical Companies Reports Adjusted EPS of $0.65 for Fourth Quarter 2009 12Par Pharmaceutical Companies Reports Adjusted EPS of $0.65 for Fourth Quarter 2009 13Par Pharmaceutical Companies Reports Adjusted EPS of $0.65 for Fourth Quarter 2009 14Par Pharmaceutical Companies Reports Adjusted EPS of $0.65 for Fourth Quarter 2009 15Par Pharmaceutical Companies Reports Adjusted EPS of $0.65 for Fourth Quarter 2009 16Par Pharmaceutical Companies Reports Adjusted EPS of $0.65 for Fourth Quarter 2009 17Par Pharmaceutical Companies Reports Adjusted EPS of $0.65 for Fourth Quarter 2009 18Par Pharmaceutical Companies Reports Adjusted EPS of $0.65 for Fourth Quarter 2009 19Zargis StethAssist & Zargis Cardioscan Cleared for Sale in Australia 2Zargis StethAssist & Zargis Cardioscan Cleared for Sale in Australia 3Zargis StethAssist & Zargis Cardioscan Cleared for Sale in Australia 4Zargis StethAssist & Zargis Cardioscan Cleared for Sale in Australia 5Zargis StethAssist & Zargis Cardioscan Cleared for Sale in Australia 6
(Date:7/30/2014)... The family of a Vermont man ... Xarelto lawsuit ( http://www.xareltolawsuitcenter.com/ ) alleging his death ... reports. According to the complaint, which was filed in ... July 25th, the decedent had been taking Xarelto for ... bleed that ultimately led to his death on August ...
(Date:7/30/2014)... (PRWEB) July 30, 2014 Hamilton ... opening of its new Carmel office on July 30th. ... will finally be moving to the state-of-the-art suite, located ... and innovative space will allow for one-on-one patient comfort, ... surgery experience. , Dr. Hamilton’s new office-suite will ...
(Date:7/30/2014)... 2014 DRE Medical — a leading ... launch of its Medical Trade Shows & Conventions ... professionals and equipment vendors. , The calendar is a ... the United States and around the world. Hundreds of ... number is always growing. , Information listed on each ...
(Date:7/30/2014)... The Technology Association of Georgia in ... (B&TA), today issued its final call for applications and ... companies have until August 29th 2014 to be considered ... selected by the Excalibur Judging Committee. Companies selected as ... judges for interviewing process. , The TAG Excalibur ...
(Date:7/30/2014)... (PRWEB) July 30, 2014 LTC Consumer, an ... long term care insurance, features an Instant Quote tool on ... and co-founder of LTC Consumer. Quotes are free and unlimited. ... click in only seven areas – including age, gender, and ... screen within seconds (you don’t need to enter any contact ...
Breaking Medicine News(10 mins):Health News:Xarelto Lawsuit Alleges Man’s Death from Uncontrollable Brain Bleeding Was Caused by Xarelto, Bernstein Liebhard LLP Reports 2Health News:Xarelto Lawsuit Alleges Man’s Death from Uncontrollable Brain Bleeding Was Caused by Xarelto, Bernstein Liebhard LLP Reports 3Health News:Hamilton Facial Plastic Surgery Opens New Carmel Office 2Health News:DRE Launches Online Interactive Medical Trade Show Calendar 2Health News:Last Call for TAG 2014 Excalibur Awards Nominations and Applications 2Health News:Last Call for TAG 2014 Excalibur Awards Nominations and Applications 3Health News:LTC Consumer Launches Online Tool for Getting Instant Long Term Care Insurance Estimates 2
... acclaimed as the "gold-standard" amongst researchers for scientific studies. ... on the other, has also questioned the worth of ... complementary and alternative medicine (CAM) practices. Majority of CAM ... cure. , ,The question arises as to whether ...
... Diabetes is the leading cause of end-stage kidney disease ... or a kidney transplant for survival. // ,A ... and the University of Heidelberg has proven that a ... kidney failure or "end-stage renal disease." ,The ...
... are facing one of the worst gastroenteritis epidemics that ... with patients coming// in droves for relief. The infection ... for a few days but seldom endangers life. ... Montreal area have reported the viral outbreak. Dr. Joseph ...
... have been created from blue green algae by scientists with ... on properties and actions of enzymes is also taken into ... possible to produce enough of the promising drugs for use ... the cover of the January issue of the journal ACS ...
... recent studies have shown that the chance of developing it ... the chances of surviving it, also depend on the same ... 50,000 pounds behind a study to be carried out by ... cancer survivors aged above fifty and with a BMI (Body ...
... detect infection of drug resistant forms of HIV even when ... the Duke University Medical Center. ,This new test ... in small amounts contrary to other tests that detect drug-resistant ... bloodstream. ,This new test is expected to be ...
Cached Medicine News:Health News:Is Evidence-based Medicine Enough to Support Additional Research in Alternative Medicine? 2Health News:A Gene Associated With Severe Kidney Failure in Diabetes Found 2Health News:Anti Cancer Drug from Blue Green Algae 2
... Small Bone Power System combines precision ... under the most exacting conditions. The ... small bone osteotomies and oral/maxillofacial procedures ... Length Available), Oscillating Saw (Extended Length ...
... The Hall® Surgical E9000® System ... offers multiple electric handpieces specifically designed ... and Oral/Maxillofacial Surgery. The E9000 System ... console and 3 specialized handpieces designed ...
... USA™ Battery Tester is ... efficiently determine if your ... Extended Run, Stryker® 2115, ... Packs contain adequate charge ...
... offers a comprehensive line of high speed ... piece construction method that minimizes breakage. Using ... polished to create the sharpest edge possible, ... procedure., ,Our high speed cutters come ...
Medicine Products: